IQVIA Holdings, Inc.

IQVIA Holdings Inc. is a global leader in advanced analytics, technology solutions, and clinical research services for the healthcare and life sciences industries. Formed from the merger of IMS Health and Quintiles, the company combines vast healthcare data assets with deep scientific expertise to help pharmaceutical, biotechnology, and medical device companies accelerate drug development and commercialization. IQVIA operates in over 100 countries, leveraging its unique data ecosystem to provide insights that improve patient outcomes and reduce healthcare costs.

IQVIA generates revenue through three primary segments: Technology & Analytics Solutions (TAS), Research & Development Solutions (RDS), and Contract Sales & Medical Solutions (CSMS). TAS provides data analytics, real-world evidence, and technology platforms to optimize commercial strategies. RDS offers clinical trial management, regulatory consulting, and laboratory services, often under long-term contracts. CSMS delivers outsourced sales and medical affairs support. Revenue is diversified across subscription-based data services, project-based fees, and performance-based contracts, with a growing emphasis on cloud-based offerings.

The company operates in the Diagnostics & Research industry within the Healthcare sector, competing with firms like LabCorp (Covance), Charles River Laboratories, and PPD (now part of Thermo Fisher). IQVIA’s competitive advantage lies in its unparalleled access to healthcare data (covering 85% of global pharmaceutical sales) and its integrated technology platform, which enables faster trial enrollment and real-time monitoring. Its scale and breadth of services create high switching costs for clients, reinforcing its market leadership.

IQVIA’s primary customers are pharmaceutical, biotechnology, and medical device companies of all sizes, as well as academic institutions and government health agencies. The company’s services are used by the top 20 global pharma firms and thousands of emerging biotechs. Geographically, revenue is heavily weighted toward North America (approximately 60%), followed by Europe and Asia-Pacific. The company is expanding in emerging markets, particularly China and India, where clinical trial activity is growing rapidly.

An auto-generated descriptive profile based on company data, for informational purposes only.